...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Brain Tumor Pathology >Analysis of immunohistochemical expression of p53 and the proliferation marker Ki-67 antigen in skull base chordomas: relationships between their expression and prognosis
【24h】

Analysis of immunohistochemical expression of p53 and the proliferation marker Ki-67 antigen in skull base chordomas: relationships between their expression and prognosis

机译：颅底脊索瘤中p53和增殖标志物Ki-67抗原的免疫组化表达分析：其表达与预后的关系

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The prognosis of chordomas is difficult to predict based solely on histological findings. The purpose of this study was to assess the immunohistochemical expression of the proliferation marker Ki-67 antigen and the expression of p53 in skull base chordomas and to relate their expressions to the outcome. We examined the expression of p53 and the MIB-1 labeling index (LI), assessed by Ki-67 expression, in 19 tumors (initial, n = 11; recurrent, n = 8) from 11 patients. The correlation among the MIB-1 LI, p53 expression, and the clinical outcome was analyzed. The mean MIB-1 LI and p53 expression at the initial surgery were 5.6 ± 4.6% and 9.0 ± 9.4%, respectively. At the time of recurrence, the mean MIB-1 LI and p53 expression were 10.2 ± 7.4% and 16.5 ± 12.0%. The correlation between the MIB-1 LI and p53 expression at the initial and recurrent surgeries was highly significant (r = 0.948; P < 0.0001). The change in p53 expression from the initial to the recurrent chordomas was significantly greater in patients who died of tumor-related causes than in the surviving patients. In the surviving patients, the values for MIB-1 LI and p53 expression in the recurrent tumors were significantly higher in the disease-ongoing group than in the disease-free group. Our results suggest that determination of the immunohistochemical expression of p53 and Ki-67 antigen is helpful to predict tumor recurrence and prognosis in skull base chordomas.
机译：仅根据组织学发现很难预测脊索瘤的预后。这项研究的目的是评估颅骨脊索瘤中增殖标志物Ki-67抗原的免疫组织化学表达和p53的表达，并将其表达与预后相关。我们检查了11例患者的19例肿瘤（初始，n = 11；复发，n = 8）中p53的表达和通过Ki-67表达评估的MIB-1标记指数（LI）。分析了MIB-1 LI，p53表达与临床结果之间的相关性。初次手术时，MIB-1 LI和p53的平均表达分别为5.6±4.6％和9.0±9.4％。复发时，平均MIB-1 LI和p53表达分别为10.2±7.4％和16.5±12.0％。初次和复发手术中MIB-1 LI和p53表达之间的相关性非常显着（r = 0.948; P <0.0001）。在死于肿瘤相关原因的患者中，从最初的脊索瘤到复发的脊索瘤，p53表达的变化明显大于幸存的患者。在幸存的患者中，疾病复发组中复发性肿瘤中MIB-1 LI和p53表达的值显着高于无病组。我们的结果表明，确定p53和Ki-67抗原的免疫组织化学表达有助于预测颅底脊索瘤的肿瘤复发和预后。

著录项

  • 来源
    《Brain Tumor Pathology》 |2007年第2期|57-62|共6页
  • 作者

    Keiichi Sakai; Kazuhiro Hongo; Yuichiro Tanaka; Jun Nakayama;

  • 作者单位

    Department of Neurosurgery Shinshu University School of Medicine Asahi 3-1-1 Matsumoto 390-8621 Japan;

    Department of Neurosurgery Shinshu University School of Medicine Asahi 3-1-1 Matsumoto 390-8621 Japan;

    Department of Neurosurgery Shinshu University School of Medicine Asahi 3-1-1 Matsumoto 390-8621 Japan;

    Department of Pathology Shinshu University School of Medicine Matsumoto Japan;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

    Skull base chordoma; MIB-1; p53; Recurrence; Prognosis;

    机译：颅底脊索瘤;MIB-1;p53;复发;预后;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号